Adalimumab was associated with significantly greater improvement in psoriasis severity, regardless of body region impacted, when compared with placebo.
The results come from a post-hoc analysis of a study which randomized 1,212 patients with moderate-to-severe psoriasis 2:1 to 80mg at week 0, followed by adalimumab 40mg or placebo every other week for 16 weeks. Psoriasis Area and Severity Index (PASI) responses and Dermatology Life Quality Index outcomes were analyzed.
PASI scores were vastly improved for all body regions examined; the trunk, head, upper extremities, and lower extremities, with scores of 83.1 ± 1.57, 81.3 ± 1.58, 75.7 ± 1.34, and 73.9 ± 1.26%, respectively (P<0.001 vs. placebo). Additionally, percentages of patients with regional PASI reduction of ≥75/≥90/100% from baseline were significantly higher with adalimumab (all P<0.001).
Trunk and head responses (77.9/65.0/59.1% and 74.6/66.1/62.8%, respectively, vs. lower) were greater than those for upper and lower extremities (67.7/45.1/39.6% and 65.7/40.0/31.3%, respectively, vs. lower).
The authors also found quality of life improvements associated with PASI responses in all body regions.
For more information visit Springer.com.